Curriculum Vitae

Bradley CAMERON Ekstrand, M.D., Ph.D.

CURRENT AFFILIATION:

 2020 – present:           Medical Director and Staff Physician

UCSF Helen Diller Cancer Center Peninsula

                                    218 De Anza Blvd.

                                    San Mateo, CA  94402

Telephone:                   (650) 341-9131

Place of Birth:             Boulder, Colorado

PRIOR AFFILIATION:

2003 – 2020:               President and Staff Physician

                                    California Cancer Care, Inc

                                    San Mateo, CA

Education:                     

1. 1997. Yale University School of Medicine

New Haven, Connecticut

M.D.

1. 1997. Yale University School of Medicine

Department of Pharmacology

New Haven, Connecticut

Ph.D., M.Phil.

Faculty Advisor:  Dr. Eric R. Fearon

1. 1990. Stanford University

Palo Alto, California

B.S. in Chemistry

POST-DOCTORAL TRAINING:

2000-2003                   Fellow in Medical Oncology

                                    Stanford University School of Medicine

                                    Stanford, California

1. 2000. Mount Sinai Medical Center

New York, New York

Internship and Residency in Internal Medicine

ACADEMIC APPOINTMENTS:

2003-2010                   Adjunct Clinical Instructor

                                    Division of Oncology, Department of Medicine

                                    Stanford University School of Medicine

                                    Stanford, CA

2002-2003                   Staff Physician and Voluntary Clinical Faculty

                                    Department of Medicine, Division of Oncology

                                    Stanford University School of Medicine

                                    Stanford, CA

1. 2000. Teaching Assistant, Department of Medicine

Mount Sinai School of Medicine

New York, New York

LICENSURE:           California Certificate: A71243

                                    April, 2000

BOARD                      American Board of Internal Medicine

CERTIFICATION:  Certified in Medical Oncology (11/2003; recertified 11/2023)        

HONORS:                 

June 1990                    Phi Beta Kappa                      

Stanford University

June 1990                    B.S. in Chemistry with Honors and Distinction

                                    Stanford University

May 2001                    Housestaff Teaching Award Nominee

                                    Department of Medicine

                                    Stanford University Medical School

March 2002                 Postdoctoral Fellow Merit Award

                                    American Society of Clinical Oncology

PROFESSIONAL SOCIETIES:

2001 – present             American Society of Clinical Oncology

                                    Member

2003 – present             Association of Northern California Oncologists

                                    Member since 2003

                                    Board of Directors since March 2007

                                    Vice President January 2014 – December 2020

PROFESSIONAL EDUCATION:

July 2002                    Workshop on Methods in Clinical Cancer Research

                                    American Society of Clinical Oncology and

                                    American Association for Cancer Research

                                    Vail, Colorado

TEACHING APPOINTMENTS:

Fall 1994                     Teaching Assistant, Upper Level Cell Biology course

                                    Department of Biology

                                    Yale College, New Haven, Connecticut

                                    Director:  Prof. Joel Rosenbaum

PUBLICATIONS:

Kwon, D.H., Trihy, L., Darvish, N., Hearst, E., Sumra, S., Borno, H.T., Bose, R., Chou, J., de Kouchkovsky, I., Desai, A., Ekstrand, B., et al. (2024) Patients can administer mobile audio recordings to increase knowledge in advanced prostate cancer. Cancer Med. 13(22):e70433

Govindan, R., Crowley, J., Schwartzberg, L., Kennedy, P., Williams, C., Ekstrand, B., et al. (2006)  Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.  J. Clin. Oncol. 24:4848-4854. 

Ekstrand, B.C., Fan, Z., Lucas, J.B., Horwitz, S.M., Breslin, S., Natkunum, Y., Bartlett, N.L., Hoppe, R.T., and Horning, S.J. (2002) Rituximab in lymphocyte predominant Hodgkin’s disease (LPHD): results of a phase II trial.  Blood 101: 4285-4289.

Ekstrand, B.C. and Horning, S.J. (2002) Lymphocyte predominant Hodgkin’s disease.  Curr. Oncol. Rep. 4: 424-433.

Ekstrand, B.C. and Horning, S.J. (2002) Hodgkin’s Disease.  Blood Reviews 16: 111-117.

Ekstrand, B.C. and Horning, S.J. (2002) Lymphocyte predominant Hodgkin’s disease: more patience than patients.  Cancer J.  8: 367-368.

Meyerhardt, J.A., Caca, K., Ekstrand, B.C., Hu, G., Legnauer, C., Banavali, S., Look, A.T., and Fearon, E.R. (1999) Netrin-1: a candidate DCC ligand is inactivated in a subset of neuroblastomas and brain tumors.  Cell Growth Diff. 10: 35-42.

Reyes-Mugica, M., Rieger-Christ, K., Ohgaki, H., Ekstrand, B.C., Helie, M., Kleinman, C., Yahanda, A., Fearon, E.R., Kleihues, P., and Reale, M.A. (1997) Loss of DCC expression and glioma progression.  Cancer Res. 57: 382-386.

Ekstrand, B.C., Mansfield, T.A., Bigner, S.H., and Fearon, E.R. (1995) DCC expression is altered by multiple mechanisms in brain tumours.  Oncogene 11: 2393-2402.

Fearon, E.R., Ekstrand, B.C., Hu, G., Pierceall, W.E., Reale, M.A., and Bigner, S.H. (1994) Studies of the deleted in colorectal cancer gene in normal and neoplastic tissues.  Cold Spring Harb. Symp. Quant. Biol. 59: 637-643.

Vreman, H.J., Ekstrand, B.C., and Stevenson, D.K. (1993) Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity.  Pediatr. Res. 33: 195-200.

ABSTRACTS PRESENTED:

Ekstrand, B.C., Lucas, J.B., Horwitz, S.M., Breslin, S., Bartlett, N.L., Hoppe, R.T., and Horning, S.J. (2002) Rituximab in lymphocyte predominant Hodgkin’s disease (LPHD): results of a phase II trial.  Proc. Amer. Soc. Clin. Oncol. 21: 264a

Ekstrand, B.C., Bigner, S.H., and Fearon, E.R. (1995)  DCC gene mutations and loss of expression in glioblastomas.  Proc. Amer. Assoc. Cancer Res. 36: 574a.

Ekstrand, B.C., Vreman, H.J., and Stevenson, D.K. (1990) Selection of heme oxygenase inhibitors based on potency and photoreactivity.  Pediatric Res. 27: 59a.  

 RESEARCH EXPERIENCE:

Ongoing experience in Phase I, II, III, and IV Clinical Pharmaceutical Trials as a Principal and/or Sub Investigator.  Completed NIH Office of Human Subjects Research training module.